Overview Request Sample Pages Request Customization Download PDF
You are viewing: Australia Biomarkers Market analysis
Part of: Biomarkers Market (Global)

The Australia Biomarkers Market was valued at $711.4 Million in 2025 and projected to reach to $1191.5 Million by 2030, representing a compound annual growth rate of 10.9%. Australia's biomarkers market is positioned for sustained expansion driven by increasing healthcare spending, growing demand for personalized medicine, and rising prevalence of chronic diseases.

Australia Biomarkers Market Trends and Insights

  • Australia's healthcare sector is increasingly adopting advanced diagnostic biomarkers to improve patient outcomes and enable precision medicine initiatives.
  • The growth trajectory reflects Australia's strong investment in healthcare infrastructure, rising prevalence of chronic diseases, and increasing demand for early disease detection and personalized treatment approaches. Driving Australia's biomarkers market expansion are advances in genomic sequencing, proteomics, and liquid biopsy technologies that enable non-invasive diagnostics.
  • Australia's regulatory environment and government support for biotechnology innovation further accelerate market penetration across oncology, cardiovascular, and infectious disease segments.
  • The forecast period through 2030 positions Australia as a key growth market within the Asia Pacific region, supported by rising healthcare expenditure and growing clinical adoption of biomarker-driven diagnostics..

Key Market Statistics

  • CAGR (2025-2030) 10.9% CAGR
  • Market Size, 2025 ~USD 711.4 Million
  • Forecast, 2030 ~USD 1191.5 Million
  • Country Australia

Australia Biomarkers Market Overview

Market Valuation Growth :

Australia's biomarkers market is valued at USD 711.4 million in 2025, with strong projected growth to USD 1,191.5 million by 2030, representing a robust 10.9% CAGR.

Precision Medicine Adoption :

Australian healthcare providers are increasingly integrating advanced diagnostic biomarkers into clinical practice to enable precision medicine initiatives and improve patient stratification.

Healthcare Infrastructure Investment :

Australia's strong investment in healthcare infrastructure and diagnostic capabilities is driving the adoption of biomarker-based testing across major medical centers and pathology networks.

Regulatory Support & Standards :

Australia's regulatory framework through TGA and NATA accreditation supports the validation and implementation of biomarker assays in clinical laboratories nationwide.

Australia Biomarkers Market Dynamics

  • The Australian healthcare system's emphasis on evidence-based diagnostics and patient outcomes is accelerating biomarker adoption across oncology, cardiovascular, and infectious disease segments.
  • Investment in research institutions and diagnostic infrastructure continues to strengthen the market foundation.
  • By 2030, Australia is expected to establish itself as a regional leader in biomarker-driven clinical decision-making, supported by government health initiatives and private sector innovation..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    In Vitro Diagnostics

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Dna Microarrays
    • Assay Kits
    • Microarrays
    Top Companies
    • ROCHE HOLDINGS AG
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Abbott Laboratories
    • Biomerieux s.a.

      Key Takeaways

      • Australia's biomarkers market is valued at USD 711.4 million in 2025 and is expected to reach USD 1,191.5 million by 2030, representing a 10.9% CAGR.
      • Australia's healthcare system is increasingly integrating precision medicine and personalized diagnostics, driving demand for advanced biomarker technologies.
      • Technological innovations in genomic sequencing, proteomics, and liquid biopsy are reshaping Australia's diagnostic landscape and expanding clinical applications.
      • Australia's supportive regulatory framework and government investment in biotechnology position the country as a growth leader within the Asia Pacific biomarkers market.

      Biomarkers Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment CANCER (Disease Indication)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.8% from 2025 to 2030
      Largest Segment CONSUMABLES (Offering)
      Market Size Base Year (Billions) ~USD 62.37 (2025)
      Revenue Forecast (Billions) ~USD 104.15 (2030)
      Segments Covered Offering, Type, Research Area, Technology, End User, Disease Indication, Application

      Australia Biomarkers Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Offering

      • Consumables
      • Services
      • Software

      By Type

      • Assay Kits
      • Efficacy Biomarkers
      • Elisa
      • Other Consumables
      • Pharmacodynamics Biomarkers
      • Predictive Biomarkers
      • Prognostic Biomarkers
      • Protein Microarrays
      • Reagents & Chemicals
      • Safety Biomarkers
      • Surrogate Biomarkers
      • Validation Biomarkers
      • Western Blot

      By Research Area

      • Genomics
      • Metabolomics
      • Other Research Areas
      • Proteomics

      By Technology

      • Chromatography
      • Immunoassays
      • Mass Spectrometry
      • Ngs
      • Other Technologies
      • Pcr

      By End User

      • Academic & Research Institutes
      • Hospitals & Diagnostic Laboratories
      • Other End Users
      • Pharmaceutical & Biotechnologies Companies
      • Pharmaceutical & Biotechnology Companies

      By Disease Indication

      • Cancer
      • Cardiovascular Disorders
      • Immunological Disorders
      • Infectious Diseases
      • Neurological Disorders
      • Other Disease Indications

      By Application

      • Clinical Diagnostics
      • Clinical Research
      • Drug Discovery & Development
      • Other Applications
      • Personalized Medicine

      Target Audience

      • In Vitro Diagnostics (IVD) Manufacturers : Need market sizing, growth forecasts, and competitive intelligence to develop biomarker assay portfolios and establish distribution partnerships across Australian pathology networks.
      • Pharmaceutical & Biotech Companies : Require insights on companion diagnostic opportunities, biomarker-driven drug development strategies, and reimbursement pathways specific to the Australian market.
      • Healthcare Providers & Pathology Labs : Seek data on emerging biomarker technologies, clinical adoption trends, and investment opportunities to enhance diagnostic capabilities and improve patient outcomes.
      • Healthcare Investors & Private Equity : Need comprehensive market analysis, growth drivers, and investment thesis to identify high-potential biomarker companies and diagnostic platforms in Australia.
      • Government & Health Policy Makers : Require market intelligence on biomarker adoption rates, healthcare spending trends, and clinical evidence to inform reimbursement policies and precision medicine initiatives.

      Key Companies in the Australia Biomarkers Market

      CompanyHQOwnershipStrongest segments
      BECKMAN COULTERUnited StatesPrivate CompanyClinical diagnostics systems (chemistry, hematology, immunoassay, urinalysis, blood bank),Laboratory automation and information systems,Life science research instruments and genomic solutions,
      PRA HEALTH SCIENCESUnited StatesPrivate CompanyClinical Research (Phase I–IV services across key therapeutic areas),Data Solutions (analytics, data platforms, and related services),
      ROSETTA GENOMICSIsraelPublic CompanyRosettaGX Cancer Origin and microRNA cancer-of-origin tests,RosettaGX Reveal (indeterminate thyroid FNA),mi-LUNG and mi-KIDNEY microRNA assays,
      TRANSGENOMIC, INC.United StatesPublic CompanyOncology and pharmacogenomics lab services,Multiplexed ICE COLD-PCR reagents,Other genomic testing technologies and platforms,
      CELGENE CORPORATIONUnited StatesPrivate CompanyREVLIMID (lenalidomide),POMALYST/THALOMID (IMiD franchise ex-REVLIMID),ABRAXANE and VIDAZA/ONUREG/ISTODAX (solid tumor and myeloid oncology),
      PFIZERUnited StatesPublic CompanyInternal medicine (cardiovascular, metabolic, respiratory, gastroenterology),Vaccines,Injectables and anti-infectives (including hospital services),
      DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology,Life Sciences,Diagnostics,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions (reagents, instruments, consumables),Analytical Instruments,Specialty Diagnostics,
      MERCK KGAAUnited StatesPublic CompanyLife Science (lab reagents, consumables, instruments, bioprocessing, CDMO/testing services),Healthcare (oncology, rare diseases, neurology/immunology, fertility, cardiovascular, metabolic/endocrine),Electronics (semiconductor materials, specialty gases, delivery equipment, display and photonics materials),
      QIAGENNetherlandsPublic CompanySample technology consumables & instruments,Molecular diagnostics assays (TB, oncology, SRH, transplant, viral load),PCR & digital PCR reagents and instruments,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITY INC.United StatesPublic CompanyDiagnostics instruments, assays, and software (prenatal, neonatal, infectious disease),Life science reagents, antibodies, and assay platforms,Detection and imaging instruments and related consumables,
      CHARLES RIVER LABORATORIESUnited StatesPublic CompanyDiscovery and Safety Assessment,Research Models and Services,Manufacturing Solutions,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Instruments and Systems,Life Science Reagents and Consumables,
      EUROFINS SCIENTIFICLuxembourgPublic CompanyFood & Feed Testing,Environment Testing,Biopharma & Clinical Diagnostics,
      BIOMéRIEUXFrancePublic CompanyClinical microbiology (culture media, ID/AST, blood culture, sepsis markers),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS),Industrial applications (food, pharma, environmental: GENE-UP, VERIFLOW, BIOBALL, TEMPO, ENDONEXT, CHEMUNEX),
      ILLUMINA, INC.United StatesPublic CompanySequencing consumables (reagents, flow cells, library prep),Sequencing instruments,Arrays and genotyping solutions,
      JSR CORPORATIONJapanPrivate CompanyDigital Solutions (lithography, photoresists, display and CMP materials),Plastics and Synthetic Resins (ABS, AES, AS, ASA),Life Sciences (diagnostic reagents, bioprocess materials, drug discovery support),
      GUARDANT HEALTHUnited StatesPublic CompanyGuardant360 (CDx and Liquid),Other oncology tests (Reveal, Tissue, OMNI, INFINITY),Shield colorectal cancer screening,
      LABCORPUnited StatesPublic CompanyRoutine and specialty diagnostics (core lab testing, women’s health, chronic disease, occupational and substance testing),Esoteric, genetic, and oncology testing (anatomic pathology, oncology, diagnostic genetics, pharmacogenetics),Biopharma Laboratory Services (central labs, development and trial-related testing),

      BECKMAN COULTER

      Beckman Coulter is a private American company founded in 1935 that employs 11,900 people. The company operates in the life sciences and diagnostics sector.

      PRA HEALTH SCIENCES

      PRA Health Sciences is a private American company founded in 1976 that employs 18,100 people. The company operates in the clinical research and contract research organization sector.

      ROSETTA GENOMICS

      Rosetta Genomics is a public Israeli company founded in 2000 with 86 employees. The company operates in the genomics and molecular diagnostics sector.

      TRANSGENOMIC, INC.

      Transgenomic, Inc. is a public American company founded in 1997 with 19 employees. The company operates in the genetic analysis and molecular diagnostics sector.

      CELGENE CORPORATION

      Celgene Corporation is a private American company founded in 1986 that employs 8,852 people. The company operates in the biopharmaceutical and oncology sector.

      PFIZER

      Pfizer is a public American company founded in 1950 with 1,244 employees. The company operates in the pharmaceutical sector.

      DANAHER CORPORATION

      Danaher Corporation is a public American company founded in 1969 that employs 59,000 people. The company operates in the life sciences, diagnostics, and environmental and applied solutions sectors.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a public American company founded in 1956 that employs 125,000 people. The company is a leading provider of laboratory equipment, reagents, and services for research and diagnostics.

      MERCK KGAA

      Merck KGaA is a public American company founded in 1668 that employs 59,077 people. The company operates in the pharmaceutical, life sciences, and performance materials sectors.

      QIAGEN

      QIAGEN is a public Dutch company founded in 1984 that employs 5,500 people. The company provides molecular diagnostics and life sciences solutions.

      ABBOTT

      Abbott is a public American company founded in 1888 that employs 115,000 people. The company operates in the diagnostics, medical devices, nutritional products, and pharmaceuticals sectors.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a public American company founded in 1999 that employs 18,000 people. The company provides analytical instruments, software, and services for life sciences and diagnostics.

      REVVITY INC.

      Revvity Inc. is a public American company founded in 1937 that employs 11,000 people. The company operates in the life sciences and diagnostics sectors.

      CHARLES RIVER LABORATORIES

      Charles River Laboratories is a public American company founded in 1947 that employs 19,000 people. The company provides preclinical and clinical laboratory services for drug development.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is a public American company founded in 1952 that employs 7,450 people. The company manufactures and distributes life science research and clinical diagnostics products.

      EUROFINS SCIENTIFIC

      Eurofins Scientific is a public Luxembourg company founded in 1987 that employs 65,694 people. The company provides laboratory testing services across multiple sectors including food, pharmaceuticals, and environmental testing.

      BIOMéRIEUX

      bioMérieux is a public French company founded in 1963 that employs 14,894 people. The company specializes in in vitro diagnostics and microbiology testing solutions.

      ILLUMINA, INC.

      Illumina, Inc. is a public American company founded in 1998 that employs 8,625 people. The company is a leader in DNA sequencing and genetic analysis technologies.

      JSR CORPORATION

      JSR Corporation is a private Japanese company founded in 1948 that employs 7,997 people. The company operates in the materials and life sciences sectors.

      GUARDANT HEALTH

      Guardant Health is a public American company founded in 2011 that employs 2,498 people. The company provides liquid biopsy and genomic testing solutions for cancer detection and monitoring.

      LABCORP

      LabCorp is a public American company founded in 1995 that employs 66,385 people. The company is a leading provider of clinical laboratory testing and drug development services.

      Reasons to Buy this Report

      • Market Size & Growth Projections : Access detailed valuation data showing Australia's biomarkers market growing from USD 711.4M to USD 1,191.5M (2025-2030), enabling accurate revenue forecasting and investment planning.
      • Competitive Landscape Analysis : Understand key players, market share distribution, and competitive positioning specific to Australia's biomarker ecosystem to identify partnership and acquisition opportunities.
      • Segment & Application Insights : Gain detailed breakdown of biomarker applications across oncology, cardiovascular, infectious disease, and other therapeutic areas relevant to Australian clinical practice.
      • Regulatory & Reimbursement Framework : Comprehensive analysis of TGA regulations, NATA accreditation requirements, and Medicare reimbursement policies affecting biomarker adoption and commercialization in Australia.
      • Strategic Market Entry Guidance : Actionable insights on market entry strategies, distribution channels, and partnership models tailored to Australia's healthcare system and regulatory environment.

      Frequently asked questions

      What is the current size of Australia's biomarkers market?

      Australia's biomarkers market was valued at USD 711.4 million in 2025 and is projected to grow to USD 1,191.5 million by 2030.

      What is the expected growth rate for Australia's biomarkers market?

      Australia's biomarkers market is expected to grow at a compound annual growth rate (CAGR) of 10.9% from 2025 to 2030.

      Which biomarker technologies are driving growth in Australia?

      Key technologies driving Australia's market include genomic sequencing, proteomics, liquid biopsy, and immunoassay-based diagnostics for precision medicine applications.

      What are the primary applications of biomarkers in Australia's healthcare system?

      Australia's biomarkers are primarily used in oncology, cardiovascular disease, infectious disease diagnostics, and personalized treatment planning across clinical settings.

      How does Australia's regulatory environment support biomarker market growth?

      Australia's Therapeutic Goods Administration (TGA) provides a supportive regulatory pathway for biomarker diagnostics, combined with government funding for biotechnology innovation and precision medicine research.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global biomarkers market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives at major market players, and industry consultants, to gather and validate critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size

      Secondary Research

      Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the global biomarkers market. The secondary sources used for this study include the American Society of Clinical Oncology (ASCO), Association for Molecular Pathology (AMP), Canadian Alliance for Healthy Hearts and Minds (CAHHM), Canadian Institute for Health Information (CIHI), Central Drugs Standard Control Organisation (CDSCO), Center for Disease Evaluation and Research (CDER), Clinical Laboratory Standards Institute (CLSI), Centers for Disease Control and Prevention (CDC), Clinicaltrials.gov, European Medicines Agency (EMA), Food and Drug Administration (FDA), GLOBOCAN, International Agency for Research on Cancer (IARC), Ministry of Food and Drug Safety (MFDS), National Cancer Institute (NCI), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), National Comprehensive Cancer Network (NCCN), National Medical Products Administration (NMPA), Organisation for Economic Co-operation and Development (OECD), Personalized Medicine Coalition (PMC), Population Health Research Institute (PHRI), Pharmaceuticals and Medical Devices Agency (PMDA), World Bank, World Health Organization (WHO), corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations, among others. These sources were also used to obtain key information on major players, market classification and segmentation aligned with industry trends, regional/country-level markets, market developments, and technology perspectives.

      Primary Research

      Following an initial assessment of the global biomarkers market landscape through secondary research, comprehensive primary research was undertaken. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were conducted with key supply-side participants, including C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% were conducted with demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephone discussions to comprehensively understand market dynamics.

      The following is a breakdown of the primary respondents:

      Biomarkers Market Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both bottom-up and top-down approaches were used to estimate and validate the total size of the global biomarkers market. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following:

      • A list of the major global players operating in the biomarkers market was generated.
      • The revenues generated from their biomarker products have been determined through annual reports and secondary sources (including paid databases)
      • The products were mapped according to the segments of the market. Percentage shares and splits were determined by each segment's revenue. This was verified using secondary sources and by industry experts.
      • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

      Biomarkers Market : Top-Down and Bottom-Up Approach

      Biomarkers Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      A biomarker is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response. Biomarkers can be molecular, histologic, radiographic, or physiological characteristics that provide valuable insights into normal and pathological processes.

      The biomarkers market encompasses a broad range of products and services that support biomarker discovery, validation, and application in clinical and research settings. This includes offerings such as consumables (assay kits, reagents, and instruments), software tools, and related services that facilitate biomarker analysis. The market report analyzes biomarker usage across multiple applications, including clinical diagnostics, drug discovery & development, personalized medicine, and clinical research. It also examines the adoption of biomarkers across key research areas, including oncology, neurology, cardiology, infectious diseases, and metabolic disorders. Furthermore, the report segments the market by type into safety, efficacy, and validation biomarkers. The study also considers regional trends, end-user adoption, and technological advancements shaping the global biomarkers landscape.

      Key Stakeholders

      • Academic & Research Institutes
      • Biomarkers Assay & Reagent Manufacturers, Vendors, and Distributors
      • Start-ups, platform technology & service providers
      • Contract Research Organizations (CROs)
      • Diagnostic product providing companies
      • Market Research and Consulting Firms
      • Pharmaceutical and Biotechnology Companies
      • Regulatory Agencies
      • Venture Capitalists
      • Forensic Labs
      • Government organizations
      • Private Research Firms
      • Contract Development and Manufacturing Organizations (CDMOs)
      • Hospitals and Diagnostic Laboratories

      Report Objectives

      • To define, describe, and forecast the global biomarkers market by offering, type, research area, technology, disease indication, application, end user, and region
      • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biomarkers market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To profile the key players in the global biomarkers market and comprehensively analyze their product & service portfolios, market positions, and core competencies
      • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations in the biomarkers market
      • To benchmark players within the biomarkers market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product & service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations to meet the company’s needs. The following customization options are available for this report:

      Portfolio Assesment

      • Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies.

      Regional Analysis

      • A further breakdown of the Rest of Asia Pacific biomarkers market into countries
      • A further breakdown of the Rest of Europe biomarkers market into countries
      • A further breakdown of the Rest of Latin America biomarkers market into countries

      Company Information

      • Detailed analysis and profiling of additional market players (up to three).

      Get the Full Biomarkers Market Report

      Full forecast, segment splits, and company analysis for all Biomarkers Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status